Driving Myocardial Infarction Market Growth in 2025: The Role of Increasing Number Of Smokers Propel Myocardial Infarction Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Myocardial Infarction Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, there has been a significant rise in the size of the myocardial infarction market. It is projected to expand from $2.05 billion in 2024 to $2.2 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.2%. The development in the past has been driven by the introduction of beta-blockers, the founding of chest pain centers, advances in thrombolytic therapies, the adoption of personalized medicine strategies, and the proliferation of wearable cardiovascular devices.

How Will the Myocardial Infarction Market Size Evolve and Grow by 2029?
Expectations are high for robust growth within the myocardial infarction market in the upcoming years, with estimates pointing to a value of $2.94 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.5%. Factors driving this anticipated growth in the forecast period include global health programs focused on cardiovascular health, increased availability of reperfusion treatments, the use of RNA therapeutics for heart-related diseases, adoption of patient-focused care methods, emphasis on microvascular dysfunction, and the advent of bioelectronic medicine. Key trends to watch for during this forecast period are progress in cardiovascular imaging, enhanced techniques in heart surgery, the rise of telemedicine, the incorporation of AI in diagnosis, the development of digital biomarkers for risk assessment, the use of blockchain for safeguarding healthcare data, AI-propelled drug discovery, and breakthroughs in heart rehabilitation technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report

What Drivers Are Propelling the Growth of Myocardial Infarction Market Forward?
The projected rise in the myocardial infarction market is attributable to the increasing prevalence of smoking. Smokers, defined as individuals who consume cigarettes, cigars, or pipe tobacco, are a key demographic in this context. The detrimental effects of cigarette smoke, particularly its ability to cause thickening and clotting of blood in veins and arteries, create the necessary conditions for myocardial infarction. In September 2023, a report from the UK's Office for National Statistics indicated that the age bracket of 25 to 34 years held the highest proportion of active smokers, making up 16.3% or roughly 1.4 million people in 2022. This figure marks a rise from the previous year when this age bracket exhibited a smoking prevalence of 15.8%, encompassing approximately 1.3 million individuals. Hence, the amplifying numbers of smokers contribute to the expansion of the myocardial infarction market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp

Which Emerging Trends Are Transforming the Myocardial Infarction Market in 2025?
Major corporations in the myocardial infarction industry are centring their efforts on the creation of innovative medications like anti-inflammatory drugs. These new drugs aim to specifically treat cardiovascular inflammation and give them a competitive advantage in the market. Anti-inflammatory medications work by decreasing inflammation in the body, relieving pain, and limiting swelling by focusing on the body's immune response. As an illustration, Agepha Pharma, a medical product manufacturer located in Slovakia, got the FDA's nod to produce its new anti-inflammatory drug, Lodoco (colchicine), in June 2023. This marks the inaugural drug that addresses the core cause of atherosclerotic cardiovascular disease. Lodoco is intended to lower the possibility of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults. It can function independently or in conjunction with cholesterol-lowering drugs. Furthermore, clinical trials revealed that Lodoco, which is a reformulated low-dose colchicine, slashed the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization by 31%.

What Are the Key Segments in the Myocardial Infarction Market?
The myocardial infarction market covered in this report is segmented -

1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb Or IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor
2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab, Eptifibatide, Tirofiban
3) By Antithrombotic Agents: Heparins, Direct Oral Anticoagulants (DOACs)
4) By Beta-Adrenergic Blockers: Metoprolol, Carvedilol
5) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate
6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril
7) By Angiotensin-Receptor Blockers: Losartan, Valsartan
8) By Analgesics: Morphine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
9) By Thrombolytics: Alteplase, Reteplase

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12164&type=smp

Who Are the Key Players Shaping the Myocardial Infarction Market's Competitive Landscape?
Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

What Geographic Markets Are Powering Growth in the Myocardial Infarction Market?
North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12164

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.